Oncocross Australia

Oncocross Australia is the Australian subsidiary of Oncocross, a South Korean biotechnology company specializing in AI-driven drug discovery and development. The company utilizes its proprietary RAPTOR AI™ platform to analyze transcriptome data, identifying new therapeutic indications for existing drugs and designing novel drug-drug combinations. Its lead program, OC514, is a small molecule combination therapy that recently completed a Phase 1 clinical trial in Australia for the treatment of sarcopenia and rare muscular diseases, including amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy (DMD). Oncocross Australia serves as a strategic hub for the company's global clinical operations, leveraging Australia's regulatory environment to accelerate early-stage development. The parent company, Oncocross Co., Ltd., is publicly traded on the KOSDAQ and maintains partnerships with several major pharmaceutical firms to expand its AI-derived pipeline.